We presented new clinical data on FT819 in lupus nephritis at the ASN Kidney Week conference this weekend. Read more about it here: shorturl.at/ILiqv and find the presentation here: shorturl.at/BTW6R $FATE
We’re in Denver for #KidneyWk26. On Saturday, Oct 24, Jonathan D. Graf, MD will give an oral presentation on FT819, our off-the-shelf CAR T-cell therapy, in lupus nephritis. $FATE
Fate welcomes Jamie Harrell as SVP, Market Development and Commercial Operations. Read more about Jamie here: shorturl.at/Pfl1n $FATE
Fate management will participate in the following fourth quarter investor conferences. Read more here: shorturl.at/IabWQ $FATE
Fate is happy to announce we have been awarded a $15M CIRM CLIN2 Grant to advance our FT819 Phase 2 study, RECLAIM-LN. Read about it here: shorturl.at/TIE1a $FATE
We're proud to share that Dr. Vaneet Sandhu, Vice President of Clinical Development, Head of Autoimmunity, joined Dr. Micah Yu on the Autoimmune Alchemy podcast for a deep dive into CAR T-cell therapies for autoimmune disease. $FATE
Available on YouTube: lnkd.in/g-6ne_wM
Fate is excited to have four presentations at the American College of Rheumatology’s Annual Convergence. Read more about the presentations here: shorturl.at/vObw7 $FATE
Fate Therapeutics to present two posters at CCR-West on Friday, September 18th. Read about it here: shorturl.at/KBQHv $FATE
Fate Therapeutics to participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference. Click here to view the webcast: shorturl.at/D2jQT $FATE
Fate Therapeutics initiates it’s potentially registrational RECLAIM-LN clinical trial and doses the first patient. Read more here: shorturl.at/YY05W $FATE
Fate Therapeutics reported Q2 2026 financial results and business highlights today. Read our full earnings press release for all the details: shorturl.at/9Wweg $FATE
FATE has received FDA clearance of its IND for FT839, a first-of-kind, 13 point edited, off-the-shelf dual-CAR T-cell co-targeting CD19 and CD38 — now advancing into Phase 1/2 development across complex, multi-system autoimmune diseases. Read more: shorturl.at/T5FxK $FATE
The Fate team will present preliminary clinical data at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting. Read more here: shorturl.at/V7GHa $FATE
Fate is excited to participate in several third quarter investor conferences. $FATE shorturl.at/Vk7sT
Fate welcomes Laura Hamill to its Board of Directors, bringing 30+ years of global commercial leadership as we advance our cell therapy programs and prepare the organization for the transition to a commercial-stage company. $FATE
Read more here: shorturl.at/Xiqaz
The FATE team presented new data on FT819 and FT839 today at the 2026 EULAR annual meeting. Read more here – shorturl.at/sXaNe $FATE #EULAR
Fate Therapeutics is at the American Society of Clinical Oncology (ASCO) Annual Meeting sharing new clinical data for FT836. $FATE ir.fatetherapeutics.com/pres…
The FATE team will present data at the upcoming annual meetings for ASCO and EULAR. Read more here – shorturl.at/dgryo $FATE
Fate Therapeutics ($FATE) reports Q1 2026 financial results and business highlights. Read our full earnings press release for all the details: shorturl.at/NXrfl
The Fate team is presenting new data this week at the ASGCT conference in Boston – Read the details here: shorturl.at/z1DLY $FATE
